Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series

Company Overview - Ernexa Therapeutics (NASDAQ: ERNA) is focused on developing innovative cell therapies for advanced cancer and autoimmune diseases [4] - The company's core technology involves engineering induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), providing a scalable, off-the-shelf treatment solution [4] Product Pipeline - The lead product, ERNA-101, is designed to activate and regulate the immune system's response to recognize and attack cancer cells, with an initial focus on ovarian cancer [5] - ERNA-201 is another cell therapy product aimed at targeting inflammation and treating autoimmune diseases [5] Upcoming Event - Sanjeev Luther, President & CEO of Ernexa, will participate in the Virtual Investor Closing Bell Series on February 25, 2026, at 4:00 PM ET, providing a corporate overview and business outlook [2][3] - Investors will have the opportunity to submit questions live during the event, with a replay available two hours after the presentation for 90 days [3]